Edition:
United States

Concert Pharmaceuticals Inc (CNCE.OQ)

CNCE.OQ on NASDAQ Stock Exchange Global Market

11.55USD
4:00pm EDT
Change (% chg)

$0.15 (+1.32%)
Prev Close
$11.40
Open
$11.49
Day's High
$11.83
Day's Low
$11.38
Volume
33,166
Avg. Vol
79,323
52-wk High
$19.82
52-wk Low
$9.23

Latest Key Developments (Source: Significant Developments)

Concert Pharma Reports Positive Results From Early-Stage Studies Testing Its Experimental Schizophrenia Treatment
Wednesday, 12 Jun 2019 07:00am EDT 

June 12 (Reuters) - Concert Pharmaceuticals Inc ::CONCERT PHARMACEUTICALS REPORTS POSITIVE RESULTS FROM PHASE 1 STUDIES EVALUATING CTP-692 IN HEALTHY VOLUNTEERS.CONCERT PHARMACEUTICALS INC - EXPECTS TO INITIATE A PHASE 2 TRIAL IN PATIENTS WITH SCHIZOPHRENIA IN Q4 OF 2019.CONCERT PHARMA - SAFETY ASSESSMENTS IN SINGLE- & MULTIPLE-ASCENDING DOSE TRIALS IN HEALTHY VOLUNTEERS SHOWED DRUG WAS WELL TOLERATED OVER DOSE RANGES TESTED.CONCERT PHARMACEUTICALS - STUDY SHOWED KEY BLOOD AND URINE MARKERS OF KIDNEY FUNCTION DID NOT INDICATE ANY SIGNS OF RENAL IMPAIRMENT.  Full Article

Concert Pharmaceuticals Says Intend To Appeal Decision From Patent Trial
Monday, 8 Apr 2019 02:45pm EDT 

April 8 (Reuters) - Concert Pharmaceuticals Inc ::CONCERT PHARMACEUTICALS ANNOUNCES DECISION FROM PATENT TRIAL AND APPEAL BOARD IN IPR PROCEEDING.CONCERT PHARMACEUTICALS INC - DISAPPOINTED IN OUTCOME FROM PATENT TRIAL AND APPEAL BOARD IN IPR PROCEEDING.CONCERT PHARMACEUTICALS INC - INTEND TO APPEAL DECISION AS WE WORK TO CREATE ADDITIONAL INTELLECTUAL PROPERTY PROTECTING CTP-543.CONCERT PHARMACEUTICALS INC - DEVELOPMENT TIMELINES FOR CTP-543 REMAIN ON TRACK..CONCERT PHARMACEUTICALS INC - DECISION IS SPECIFIC TO CERTAIN PATENT CLAIMS COVERING CTP-543 AND DOES NOT AFFECT OTHER PROGRAMS IN PORTFOLIO.  Full Article

Concert Pharmaceuticals Reports Year Ended 2018 Financial Results
Thursday, 28 Feb 2019 07:00am EST 

Feb 28 (Reuters) - Concert Pharmaceuticals Inc ::CONCERT PHARMACEUTICALS REPORTS YEAR ENDED 2018 FINANCIAL RESULTS AND PROVIDES UPDATE ON CLINICAL PROGRAMS.CONCERT PHARMACEUTICALS INC - CTP-692 POISED TO ADVANCE INTO PHASE 2 DEVELOPMENT BY YEAR END 2019 AS ADJUNCTIVE TREATMENT FOR SCHIZOPHRENIA.CONCERT PHARMACEUTICALS INC - REVENUE WAS $10.5 MILLION FOR YEAR ENDED DECEMBER 31, 2018, COMPARED TO $143.9 MILLION FOR YEAR ENDED DECEMBER 31, 2017.  Full Article

Concert Pharmaceuticals Reports Positive Results For CTP-543
Monday, 12 Nov 2018 07:00am EST 

Nov 12 (Reuters) - Concert Pharmaceuticals Inc ::CONCERT PHARMACEUTICALS REPORTS POSITIVE CTP-543 RESULTS FROM INTERIM ANALYSIS OF PHASE 2A TRIAL IN PATIENTS WITH ALOPECIA AREATA.CONCERT PHARMACEUTICALS INC - CTP-543 ACHIEVED ITS PRIMARY ENDPOINT IN 8 MG TWICE-DAILY COHORT.CONCERT PHARMACEUTICALS INC - NO SERIOUS ADVERSE EVENTS WERE REPORTED.CONCERT PHARMACEUTICALS - RESULTS FROM COMPLETE CTP-543 PHASE 2A TRIAL, INCLUDING 12 MG COHORT, EXPECTED IN Q3 2019.  Full Article

Concert Pharmaceuticals Amends Protocol Of Phase 2A Trial To Evaluate 12 Mg Twice-Daily Dose Cohort Of Ctp-543 For Treatment Of Alopecia Areata
Wednesday, 26 Sep 2018 07:00am EDT 

Sept 26 (Reuters) - Concert Pharmaceuticals Inc ::CONCERT PHARMACEUTICALS AMENDS PROTOCOL OF PHASE 2A TRIAL TO EVALUATE 12 MG TWICE-DAILY DOSE COHORT OF CTP-543 FOR THE TREATMENT OF ALOPECIA AREATA.CONCERT PHARMACEUTICALS INC - COMPANY ON TRACK TO REPORT TOPLINE DATA FROM 4 MG AND 8 MG TWICE-DAILY COHORTS IN Q4 OF 2018.CONCERT PHARMACEUTICALS INC - PROTOCOL AMENDMENT PROVIDES FOR ADDITIONAL PATIENTS TO BE ENROLLED IN TRIAL.  Full Article

Concert Pharma Says FDA Granted Fast Track Designation To CTP-543
Friday, 12 Jan 2018 07:05am EST 

Jan 12 (Reuters) - Concert Pharmaceuticals Inc ::FDA GRANTS FAST TRACK DESIGNATION TO CONCERT PHARMACEUTICALS’ CTP-543 FOR THE TREATMENT OF ALOPECIA AREATA.CONCERT PHARMA SAYS U.S. FDA GRANTED FAST TRACK DESIGNATION FOR CO'S CTP-543.  Full Article

Concert Pharmaceuticals Announces Appointment Of Marc Becker As CFO
Monday, 18 Dec 2017 07:00am EST 

Dec 18 (Reuters) - Concert Pharmaceuticals Inc ::CONCERT PHARMACEUTICALS ANNOUNCES THE APPOINTMENT OF MARC BECKER AS CHIEF FINANCIAL OFFICER.CONCERT PHARMACEUTICALS INC - ANNOUNCED APPOINTMENT OF MARC BECKER AS CHIEF FINANCIAL OFFICER, EFFECTIVE JANUARY 4, 2018.  Full Article

Concert Pharmaceuticals reports Q3 earnings per share $5.61
Thursday, 9 Nov 2017 07:00am EST 

Nov 9 (Reuters) - Concert Pharmaceuticals Inc :Concert Pharmaceuticals reports third quarter 2017 financial results and provides company update.Q3 earnings per share $5.61.Q3 revenue $143.8 million.Q3 revenue view $11,700 -- Thomson Reuters I/B/E/S.Q3 earnings per share view $-0.54 -- Thomson Reuters I/B/E/S.Concert Pharmaceuticals Inc - ‍Expects cash, cash equivalents and investments as of September 30, 2017 to be sufficient to fund company into 2021​.  Full Article

Concert Pharmaceuticals announces completion of enrollment in First Cohort of CTP-543 phase 2a trial
Monday, 6 Nov 2017 07:00am EST 

Nov 6 (Reuters) - Concert Pharmaceuticals Inc :Concert Pharmaceuticals Inc announces completion of enrollment in First Cohort of CTP-543 phase 2a trial.Concert Pharmaceuticals Inc - ‍phase 2a trial on track to complete in second half of 2018​.  Full Article

Concert Pharma Says PTAB denies Incyte petition challenging CTP-543 patent
Thursday, 19 Oct 2017 01:00pm EDT 

Oct 19 (Reuters) - Concert Pharmaceuticals Inc ::Concert Pharma says patent trials and appeal board of u.s. patent and trademark office has denied Incyte's petition to institute IPR​.  Full Article